*PENILE TRAUMA: AN ETIOLOGIC FACTOR IN PEYRONIE'S DISEASE AND ERECTILE DYSFUNCTION, Jarow JP, Lowe FC, The Journal of Urology- 1997 10 (Vol. 158, Issue 4)
*Plantar Fibromatosis. Orthopeadic Knowledge Update. Foot and Ankle. American Foot and Ankle Society. p.23, 1994. Edited by Lowel D. Lutter, Mark S. Mizel, Glenn B. Pfeffer. Published by AAOS.
*Rayan GM. Clinical presentation and types of Dupuytren's disease. Hand Clin 1999;15: 87-96, vii.[ISI][Medline]
The information contained in this website is provided for educational purposes only and is not intended to replace discussions with your healthcare provider. All decisions regarding a patients' treatment must be made with a healthcare provider. PDLabs is not an "internet pharmacy" and requires that an appropriate doctor-patient-pharmacist relationship be maintained. PDLabs will not fill prescriptions for patients that do not have a valid patient-doctor relationship.
Parsons' Solution is available as a compounded medication and has been licensed to PDLabs by Urigen Pharmaceuticals, Inc. US Patents 7,414,039 and additional patents pending. Parsons' Solution is not FDA approved.
Transdermal Verapamil 15% Gel is available as a compounded medication exclusively from PDLabs. Transdermal Verapamil 15% Gel is not FDA approved.
Transdermal Verapamil 15% Gel is not for everyone. Patients with specific heart conditions known as atrioventricular (AV) block or Sino-Atrial (SA) block should not use calcium channel blockers such as verapamil. Patients taking the antiarrhythmic drug Tikosyn® (Dofetilide) should not use Transdermal Verapamil 15% Gel.
Patients taking digoxin or cyclosporine should have their drug levels monitored on a regular basis as verapamil may decrease the metabolism and clearance of these drugs. Patients taking antiarrhythmic drugs should consult with their doctor before taking Transdermal Verapamil 15% Gel to ensure it is safe to use. A PDLabs pharmacist can help with this discussion.
The most common side effect reported with Transdermal Verapamil 15% Gel, affecting 3-5% of Peyronie's disease patients, is varying degrees of skin irritation. Some patients using the medication for the first time may experience mild itching/irritation during the first few days of treatment. This is normal and usually resolves within 3-4 days. Other patients may experience more severe contact dermatitis, including itching, burning, redness, or swelling. More persistent or severe irritation can usually be treated with topical corticosteroids. Based on the individual symptoms, PDLabs will work with the patient and prescribing physician to determine the best course of treatment to resolve irritation.